Lyra Therapeutics, Inc. announced the appointment of Robert Richard, Ph.D., to the position of Senior Vice President of Research and Development. He is a research and development (R&D) veteran who possesses extensive leadership and product development experience in drug delivery and complex combination products. Dr. Richard will oversee development for Lyra’s two product candidates for the treatment of chronic rhinosinusitis, and lead efforts on platform expansion, including next generation technologies that support new indications. Dr. Richard previously held leadership positions with Anika Therapeutics, C.R. Bard, Boston Scientific, and Johnson & Johnson, where he led R&D organizations through numerous product development initiatives from the concept through to commercialization. At Boston Scientific, Dr. Richard helped lead the development and launch of the TAXUS™ drug eluting coronary stent. Most recently, he led the global R&D organization at Anika Therapeutics, where he directed the launch of TACTOSET™.